To provide high-quality target enrichment solutions to the genomics community to advance precision medicine and research.
Headquartered in the San Francisco Bay Area, Paragon Genomics is a fast-growing precision medicine company. Our patented targeted sequencing technologies CleanPlex® DNA, CleanPlex® RNA, CleanPlex® UMI, and OmniFusion™ provide comprehensive solutions to precision oncology, infectious disease testing, inherited disease testing, single cell analysis, molecular breeding and many other applications. Our technologies and products have been adopted by hundreds of prominent Next-Generation Sequencing (NGS) labs globally. With our platforms, we can efficiently and rapidly produce unique and customized next-generation sequencing (NGS) assays to meet the needs of researchers, testing labs and biopharma precision medicine projects.
Paragon Genomics’ COVID-19 NGS assay developed within one month is a great example about how fast we can develop a high-quality NGS assay. This assay has been widely adopted by researchers and clinicians globally to fight the COVID-19 pandemic.
Who We Are
At Paragon Genomics, we are a passionate group dedicated to providing cutting-edge technologies and solutions for the global genomic research and application community. Our goal is to move precision medicine forward. The team is composed of industry veterans and academic experts who previously worked with well-known industry leading companies and institutions such as ThermoFisher Scientific, Life Technologies, PerkinElmer, Beckman Coulter, Affymetrix, Novartis, Applied Biosystems, Siemens Healthcare, Stanford and Harvard.
Paragon Genomics’ leadership team proudly graduated from the California Life Sciences Institute’s (CLSI) Spring 2016 FAST Advisory Program. We were also honored to be accepted into the renowned StartX Fall 2016 Accelerator Program.
Tao Chen, MBA
Co-Founder and CEO
Zhitong Liu, PhD
Co-Founder and CTO
Product & Tech Support
Jin Billy Li, PhD
Associate Professor, Stanford University
Wayne Tam, MD, PhD
Professor, Weill Cornell Medicine
Joe Keegan, PhD
Director, Interpace Diagnostics
CEO, AYOXXA Biosystems GmbH
Gary Zweiger, PhD